Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 26

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 1
Chunk 26
---
2023, October 20, 2023, November 21, 2023 and December 6, 2023 respectively.
On December 14, 2023, HoldCo filed a notice of effectiveness. On January 9, 2024, our shareholders held a Business Combination Meeting
and voted in favor of approving the Longevity Business Combination. 

On
June 26, 2024, pursuant to Section 11.1(a) of the Longevity Merger Agreement, the parties entered into a termination agreement (the “Termination
Agreement”) pursuant to which the Longevity Merger Agreement was terminated effective as of the date of the Termination Agreement. 

As
a result of the Termination Agreement, the Longevity Merger Agreement will be of no further force and effect (other than certain customary
limited provisions that survive the termination pursuant to the terms of the Longevity Merger Agreement) and ancillary agreements entered
into in connection with the Longevity Merger Agreement will also automatically terminate in accordance with their respective terms. As
a result of the termination of the Longevity Merger Agreement, Holdco filed the Registration Withdrawal Request on Form RW on August
9, 2024, to withdraw its registration statement on Form S-4, as amended, initially filed with the SEC on March 29, 2023.   

On
July 2, 2024, the Company issued a press release to announce that it entered into a letter of intent with Semnur Pharmaceuticals, Inc.
(“Semnur”), a wholly owned subsidiary of Scilex Holding Company (“Scilex”), for a potential business combination.

On
July 10, 2024, the shareholders of the Company held an extraordinary general meeting of shareholders (the “Shareholder Meeting”)
to consider and vote upon a proposal to amend, by way of special resolution, the Articles to extend the date by which the Company must:
(i) consummate a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination involving
the Company and one or more businesses or entities (an “initial business combination”); (ii) cease its operations, except
for the purpose of winding up, if it fails to complete such initial business combination; and (iii) redeem 100% of the Company’s
Class A ordinary shares, par value $0.0001 per share (the “Class A ordinary shares”), included as part of the